openPR Logo
Press release

OX-40 Receptor Agonist Therapeutics Analysis - Patent, Designation, Collaboration and Developments

08-16-2018 08:11 AM CET | Health & Medicine

Press release from: P&S Intelligence - Pharmaceuticals

OX-40 Receptor Agonist Therapeutics Analysis - Patent,

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

Browse report at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OX-40 Receptor Agonist Therapeutics Analysis - Patent, Designation, Collaboration and Developments here

News-ID: 1181564 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.

All 5 Releases


More Releases for GlaxoSmithKline

Oncology Drugs Market Competitive Outlook - GlaxoSmithKline, Novartis, Merck
"The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to
Rabies Treatment Market 2025 | Sanofi, GlaxoSmithKline, Cadila Healthcare
Global Rabies Treatment Market: Overview Rabies is a neural disease caused by a virus. It affects humans and several other mammals, with dogs, bats, raccoons, and cats being among the most common victims. Rabies causes inflammation of the brain, leading to fever, loss of control over body parts, and a fear of water. Rabies treatment is a key concern despite the relatively limited spread of the disease, as rabies is almost
Biotechnology Market – Encouraging Transformation 2025 | Genentech, GlaxoSmith …
Global Biotechnology Market: Overview The global biotechnology market is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. The advent of stem cell technology, nanotechnology, and cloning has also propelled this market substantially and is expected to continue aiding to this market in the years to come. However, the dearth of awareness among consumers
Comprehensive Study On Chocolate Powder Market 2018 Global Analysis By Key Manuf …
Nestle, Mars, PepsiCo, Mondelez, GlaxoSmithKline, GlaxoSmithKline, Kanegrade are the leading companies and brands that are driving the Chocolate Powder Market. The CAGR numbers are looking quite impressive for the forecast period of 2018-2023 in the Chocolate Powder Market. The sales, import, export and revenue figures are also skyrocketing in the forecast period. The key players and brands are making their moves by product launches, their researches, their joint ventures, merges,
Chocolate Powder Market 2018: Global Industry Analysis By Top Key Players(Nestle …
Report Covers: “Chocolate Powder” Market Size, Status and Forecast 2023 provides Market information about industry Top Key Players, Countries, Type and Application. This Chocolate Powder Industry report also states Company Profile, Competitive analysis, Chocolate Powder Market revenue and price, market share, market growth and gross margin by regions Company (Nestle, Mars, PepsiCo, Mondelez, GlaxoSmithKline, GlaxoSmithKline, Kanegrade, ProBlends etc.): Market Research Methodology: We prepare our reports by collecting primary data through interviews of opinion
Cytokines Market 2017 - AbbVie, Johnson & Johnson, GlaxoSmithKline, Sanofi
Apex Research, recently published a detailed market research study focused on the "Cytokines Market" across the global, regional and country level. The report provides 360° analysis of "Cytokines Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Cytokines industry, and estimates the future trend of Cytokines market on the basis of this